Medicines For Europe Country Specific Market Access Policies

Positioning Statements on Physician-led Switching for Biosimilar Medicines

IGBA position on identification of biological, including biosimilar medicines (2018 update of facts & figures)

Biosimilar Medicines Reading List

7. Biosimilar Medicines_ReadingList-1

The impact of SPC Manufacturing Waiver on jobs, competitiveness & patient access to medicines

16th Biosimilar Medicines Conference

14th Legal Affairs Conference

17th Regulatory and Scientific Affairs Conferenc

11th Medicines for Europe Pharmacovigilance Conference

IGBA 2017 achievements – Adrian van den Hoven